In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue

Proposed legislation in the US House of Representatives seeks to limit patent term extension for pharmaceutical products in a way that pharma innovators say would stifle innovation and not solve potential drug pricing problems. Read More... 

With the EU SPC Manufacturing Waiver due to come into force next week, innovators, generics and patent offices say that they are looking at which products might be affected and whether to charge notification fees. Read more... 

In-house counsel say they would have preferred to have seen more robust changes in the fourth amendment to China’s Patent Law as well as better predictability of rulings. Read more... 

With insurtech patents increasing by 40% in 2017, in-house counsel at Allstate, The Hartford and elsewhere say filings will continue to go up as they seek to become more customer-centric organisations. Read more...